CTCA FORUM 2014

Welcome

Goal

The goal of the CTCA FORUM is to review and discuss the evidence supporting systemic and surgical strategies when treating patients with colorectal cancer and peritoneal carcinomatosis. This program is unique in its format – participants will be invited to contribute their perspectives on the questions and controversies that surround the development of standards of care for these patients.

Educational Objectives

After attending the CTCA FORUM, participants should be able to:

  • Discuss current options for treating patients with colorectal cancer and peritoneal carcinomatosis
  • Evaluate the clinical trial evidence supporting the efficacy of systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer and peritoneal carcinomatosis
  • Assess the utility of hyperthermic intraperitoneal chemotherapy for treating patients with colorectal cancer and peritoneal carcinomatosis
  • Identify patient candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Target Audience

The CTCA FORUM will be developed to meet the educational needs of healthcare providers involved in the care of oncology patients, including surgical oncologists, medical oncologists, radiation oncologists, diagnostic radiologists, pathologists, surgical and medical oncology fellows, and resident trainees.

Educational Methods

• Interactive Presentations
• Patient Case Presentations
• Faculty Panel
• Question and Answer Sessions

Course Evaluation

CTCA FORUM participants will receive a course evaluation form to provide an opportunity to comment on any perceived commercial bias in the presentations, as well as to identify future educational topics. In addition, participants will have the opportunity to comment on the value of the program content on their practice decisions, performance improvement activities, or possible impact on patient health status.

Accreditation/Credit Designation

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Dannemiller and Athena Education Group. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians. Dannemiller designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the program.

As a provider accredited by ACCME, Dannemiller must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgment regarding the presentation.

CME Certificates and Attendance and Verification Certificates

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed after the meeting. To obtain a CME certificate, healthcare providers must submit a completed evaluation survey. Upon request, a record of attendance certificate will be provided to other oncology care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional medical associations.

Unapproved Uses of Drugs/Devices

In accordance with requirements of the Food and Drug Administration (FDA), the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing information.

Americans with Disabilities Act (ADA)

Dannemiller and Athena fully comply with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please email wendy.gloffke@athenaedgroup.com by July 1, 2014 in order to receive appropriate services at the conference.

For More Information

Please contact:
Athena Education Group, LLC
Attention: Wendy Gloffke
River Walk, Building A
201 South Main Street, Suite 15
Lambertville, NJ USA 08530
Tel (609) 903-1005
Fax (609) 460-4127
Email wendy.gloffke@athenaedgroup.com




Dannemiller Athena Education Group

Jointly provided by Dannemiller and Athena Education Group.

Dannemiller and Athena Education Group gratefully acknowledge an educational grant from the Cancer Treatment Centers of America® in support of this continuing education activity.



  CTCA logo

 

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top